Vol. 5 No. 9 (2025)
Reimbursement Reviews

Trabectedin

Published September 10, 2025

Key Messages

  • Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
  • The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception of Quebec.
  • This review assesses trabectedin, 1 mg per vial, sterile lyophilized powder for IV injection through a central line.
  • Indication: Trabectedin in combination with doxorubicin for the first-line treatment of advanced unresectable or metastatic uterine or soft tissue leiomyosarcoma in adults.